创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

陈红, 胡洪波. 靶向T细胞发育药物研究进展[J]. 药学进展, 2022, 46(8): 631-640. DOI: 10.20053/j.issn1001-5094.2022.08.007
引用本文: 陈红, 胡洪波. 靶向T细胞发育药物研究进展[J]. 药学进展, 2022, 46(8): 631-640. DOI: 10.20053/j.issn1001-5094.2022.08.007
CHEN Hong, HU Hongbo. Progress of Research on Drugs Targeting T Cell Development[J]. Progress in Pharmaceutical Sciences, 2022, 46(8): 631-640. DOI: 10.20053/j.issn1001-5094.2022.08.007
Citation: CHEN Hong, HU Hongbo. Progress of Research on Drugs Targeting T Cell Development[J]. Progress in Pharmaceutical Sciences, 2022, 46(8): 631-640. DOI: 10.20053/j.issn1001-5094.2022.08.007

靶向T细胞发育药物研究进展

Progress of Research on Drugs Targeting T Cell Development

  • 摘要: T细胞是适应性免疫系统的主要组成部分,其发育和成熟在胸腺内完成。T细胞受体多样性是T细胞识别和应答多种抗原的重要基础,但胸腺在衰老过程中发生萎缩导致胸腺功能受损,初始T细胞输出减少。综述目前临床上使用的促进胸腺T细胞发育的药物的研究进展,以期为免疫功能受损患者恢复适应性免疫提供参考。

     

    Abstract: T cells are the major players in adaptive immunity and thymus is the crucial organ for T cell development and maturation.The diversity of T cell receptors is an important basis for T cells to recognize and respond to diverse antigens, yet thymus undergoes agingrelated involution leading to impaired thymic function and decreased naïve T cell generation. This review summarizes the current progress of research on clinically used drugs promoting thymic T cell development, in order to provide reference for patients with impaired immune function to restore adaptive immunity.

     

/

返回文章
返回